Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Surprise: Winter is Over but Not the Flu; polyDNA Recommends Talking to the Doctor about Gene-Eden-VIR
  • USA - English


News provided by

PolyDNA

Apr 19, 2014, 03:00 ET

Share this article

Share toX

Share this article

Share toX


We recommend individuals talk to their doctors about Gene-Eden-VIR. This natural antiviral was proven to reduce viral symptoms in a post-marketing clinical study that followed FDA guidelines. – Mike Evans, polyDNA

Post this

Rochester, NY (PRWEB) April 19, 2014 -- polyDNA has learned that flu cases have surprisingly increased as 2014 unfolds. Dr. Robert Glatter said that he has seen an increase in patients, “which is common during the winter flu season - but this is April (1).” The doctor continued, saying that “People stay indoors longer and because they stay indoors longer there is a greater chance that they can spread the virus among themselves (1).” To make matters worse, “Those suffering are not only those who failed to get vaccinated but also those that did. The flu shot prevents only 75% to 80% of flu strains (1).” If someone suspects that they’re coming down with the flu, polyDNA recommends talking to the doctor about Gene-Eden-VIR, a natural antiviral proven to reduce viral symptoms in a post-marketing clinical study that followed FDA guidelines.

The CDC says that, during this flu season almost twice as many people were hospitalized because of the flu virus compared to previous years. In fact, “People aged 18-64 account for 61 percent of influenza hospitalizations, compared to 35 percent for that age range in past years.” (See the UniversityHerald.com, from February 21, 2014) (2). Moreover, more than half of these hospitalizations are of young people. “People aged 25-64 have also accounted for more than half of all flu-related deaths (2).”

“Influenza (flu) is a contagious respiratory illness caused by influenza viruses. It can cause mild to severe illness. Serious outcomes of flu infection can result in hospitalization or death.” (See the CDC, last updated September 12, 2013) (3). Thus the CDC is urging vaccination “since flu season may not end until early spring (2).”

However, some research shows that the flu vaccine is only partially effective, and that a person’s immunity against the flu quickly disappears. “These results suggest a low preventive effect of the 2011/12 seasonal influenza vaccine, and a decline in VE (vaccine effectiveness) with time since vaccination.” (See the European medical journal Eurosurveillance, from January 31, 2013) (4).

Dr. Anne Schuchat said, “I want to remind you that the season is not over. There is still a lot of influenza circulating. If you haven’t been vaccinated yet, it’s not too late for you to benefit.” (See CNN, from February 20, 2014) (5). Dr. Schuchat is the director of the National Center for Immunization and Respiratory Diseases. In addition, Dr. Tom Frieden, director of the CDC, said, “Influenza can make anyone very sick, very fast and it can kill (5).”

polyDNA believes that individuals concerned about the flu virus should talk to their doctors about Gene-Eden-VIR. polyDNA would like to remind the public that, “The prevalence of chronic viral infectious diseases, such as … influenza virus…and resistance to currently used antiviral drugs have led to increased demand for new antiviral strategies and reagents.” (See Trends in Pharmacological Sciences, from February 2014) (6).

“We recommend individuals talk to their doctors about Gene-Eden-VIR. This natural antiviral was proven to reduce viral symptoms in a post-marketing clinical study that followed FDA guidelines.” – Mike Evans, polyDNA

A study published on August 12, 2013 in the peer reviewed, medical journal Pharmacology & Pharmacy, in a special edition on Advances in Antiviral Drugs, showed that Gene-Eden-VIR reduced viral symptoms. Study authors wrote that, “Individuals… reported a safe decrease in their symptoms following treatment with Gene-Eden-VIR (7).” The post marketing study authors also wrote that, “We observed a statistically significant decrease in the severity, duration, and frequency of symptoms (7).”

To learn more about Gene-Eden-VIR, visit http://www.gene-eden-vir.com. All orders of Gene-Eden-VIR are completely confidential, and no information is shared or sold to any third party. Privacy is assured.

###

References:

(1) Prolonged winter is turning this spring into flu season. Published on April 10, 2014.
http://pix11.com/2014/04/10/prolonged-winter-is-turning-this-spring-into-flu-season/#axzz2yla4IAim

(2) Flu Season Not Over Yet: Why So Many Younger People Are Being Hospitalized for Influenza. Published on February 21, 2014.
http://www.universityherald.com/articles/7675/20140221/flu-season-not-over-yet-why-so-many-younger-people-are-being-hospitalized-for-influenza.htm

(3) CDC - Seasonal Influenza (Flu). Last updated September 12, 2013.
http://www.cdc.gov/flu/about/disease/index.htm

(4) Decline in Influenza Vaccine Effectiveness with Time After Vaccination, Navarre, Spain, Season 2011/12. Published on January 31, 2013.
http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20388

(5) Flu hitting young people harder this year. Published on February 20, 2014.
http://edition.cnn.com/2014/02/20/health/flu-hits-young-people/

(6) Current progress in antiviral strategies. Published in February 2014.
http://www.ncbi.nlm.nih.gov/pubmed/24439476

(7) Gene-Eden-VIR Is Antiviral: Results of a Post Marketing Clinical Study. Published on August 12, 2013.
http://www.scirp.org/journal/PaperInformation.aspx?PaperID=36101#.U0qDXVWSz90

polyDNA is a biotechnology company that develops dietary supplements using the unique scientific method developed by Dr. Hanan Polansky, which is based on Computer Intuition.

In addition to his unique scientific method, Dr. Polansky published the highly acclaimed scientific discovery, called Microcompetition with Foreign DNA. The discovery explains how foreign DNA fragments, and specifically, DNA of latent viruses, cause most major diseases.

polyDNA developed Gene-Eden-VIR, an antiviral natural remedy that helps the immune system kill latent viruses.

Mike Davis, PolyDNA, http://gene-eden-kill-virus.com/, +1 5852509999, [email protected]

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.